

# Pu-Yuan Xing

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9295855/pu-yuan-xing-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64

papers

545

citations

12

h-index

21

g-index

80

ext. papers

828

ext. citations

3.4

avg, IF

3.77

L-index

#	Paper	IF	Citations
64	A real-world study of dacomitinib in later-line settings for advanced non-small cell lung cancer patients harboring EGFR mutations.. <i>Cancer Medicine</i> , <b>2022</b> ,	4.8	1
63	Apatinib as maintenance therapy following standard first-line chemotherapy in extensive disease small cell lung cancer: A phase II single-arm trial.. <i>Thoracic Cancer</i> , <b>2022</b> ,	3.2	1
62	Intracranial efficacy of alectinib in ALK-positive NSCLC patients with CNS metastases-a multicenter retrospective study.. <i>BMC Medicine</i> , <b>2022</b> , 20, 12	11.4	2
61	Immune checkpoint inhibitor rechallenge in advanced or metastatic non-small cell lung cancer: a retrospective cohort study.. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2022</b> , 1	4.9	1
60	First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for -altered NSCLC: a retrospective real-world POLISH study.. <i>Therapeutic Advances in Medical Oncology</i> , <b>2022</b> , 14, 17588359221082339	5.4	1
59	Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (-TKI) in -Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients.. <i>Cancer Management and Research</i> , <b>2022</b> , 14, 863-873	3.6	0
58	Clinical significance of ALDH1A1 expression and its association with E-cadherin and N-cadherin in resected large cell neuroendocrine carcinoma.. <i>Translational Oncology</i> , <b>2022</b> , 19, 101379	4.9	
57	Efficacy of first-line treatments in the elderly and non-elderly patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: a network meta-analysis.. <i>BMC Cancer</i> , <b>2022</b> , 22, 514	4.8	1
56	Cerebrospinal Fluid Cell-Free DNA-Based Detection of High Level of Genomic Instability Is Associated With Poor Prognosis in NSCLC Patients With Leptomeningeal Metastases.. <i>Frontiers in Oncology</i> , <b>2022</b> , 12, 664420	5.3	1
55	Efficacy of dacomitinib in patients with EGFR-mutated NSCLC and brain metastases. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 3407	3.2	2
54	Clinical outcome, long-term survival and tolerability of sequential therapy of first-line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China. <i>Thoracic Cancer</i> , <b>2021</b> ,	3.2	1
53	ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer. <i>Molecular Medicine</i> , <b>2021</b> , 27, 138	6.2	2
52	Exploration of the Tumor-Suppressive Immune Microenvironment by Integrated Analysis in -Mutant Lung Adenocarcinoma. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 591922	5.3	2
51	Identification of predictive biomarker for immunotherapy by associating with CD8+T cell Infiltration in lung adenocarcinoma.. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, e21177-e21177	2.2	
50	Concurrent chemotherapy and first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first-line treatment in advanced lung adenocarcinoma harboring an EGFR mutation. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2233-2240	3.2	1
49	Clinicopathological features and prognostic analysis of 247 small cell lung cancer with limited-stage after surgery. <i>Human Pathology</i> , <b>2021</b> , 108, 84-92	3.7	1
48	Clinicopathological features and prognostic implications of ASCL1 expression in surgically resected small cell lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 40-47	3.2	2

47	Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 1	4.9	2
46	Efficacy and safety profile of combining programmed cell death-1 (PD-1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2360-2368	3.2	1
45	Study protocol: A single-arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first-line immunotherapy. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2825-2828	3.2	3
44	Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2749-2757	3.2	3
43	Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 713483	5.3	1
42	Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2585-2593	3.2	2
41	Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 2924-2932	3.2	2
40	YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes. <i>Lung Cancer</i> , <b>2021</b> , 160, 166-174	5.9	2
39	Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis.. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2021</b> , 2021, 9311875	2.3	3
38	ASCL1 and DLL3 expressions and their clinicopathological implications in surgically resected pure small cell lung cancer: A study of 247 cases from the National Cancer Center of China.. <i>Thoracic Cancer</i> , <b>2021</b> ,	3.2	1
37	Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2020</b> , 146, 2427-2433	4.9	19
36	Clinical Characteristics and Treatment Outcomes of 65 Patients With BRAF-Mutated Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 603	5.3	12
35	Clinical activity and safety profile of dacomitinib in advanced epidermal growth factor receptor-positive non-small cell lung cancer patients with brain metastases.. <i>Journal of Clinical Oncology</i> , <b>2020</b> , 38, e21656-e21656	2.2	1
34	The clinical significance of RET gene fusion among Chinese patients with lung cancer.. <i>Translational Cancer Research</i> , <b>2020</b> , 9, 6455-6463	0.3	1
33	Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association. <i>Cancer Biology and Medicine</i> , <b>2020</b> , 17, 896-909	5.2	5
32	Whole exome sequencing (WES) analysis of transformed small cell lung cancer (SCLC) from lung adenocarcinoma (LUAD). <i>Translational Lung Cancer Research</i> , <b>2020</b> , 9, 2428-2439	4.4	5
31	Changes and Influential Factors of Chemotherapy Usage for Non-Small Cell Lung Cancer Patients in China: A Multicenter 10-Year (2005-2014) Retrospective Study. <i>Cancer Management and Research</i> , <b>2020</b> , 12, 6033-6044	3.6	
30	Comparative study of clinicopathological characteristics and prognosis between combined and pure small cell lung cancer (SCLC) after surgical resection. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2782-2792	3.2	10

29	Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib. <i>Targeted Oncology</i> , <b>2019</b> , 14, 335-342	5	19
28	Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5212-5220	12.9	33
27	Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China. <i>BMJ Open</i> , <b>2019</b> , 9, e028589	3	1
26	What are the clinical symptoms and physical signs for non-small cell lung cancer before diagnosis is made? A nation-wide multicenter 10-year retrospective study in China. <i>Cancer Medicine</i> , <b>2019</b> , 8, 4055-4069	4.8	12
25	Efficacy and safety of afatinib in a Chinese population with advanced lung adenocarcinoma with sensitive EGFR mutations. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1461-1468	3.2	7
24	Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China. <i>Targeted Oncology</i> , <b>2019</b> , 14, 325-333	5	3
23	Distribution of ALK Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib. <i>Targeted Oncology</i> , <b>2019</b> , 14, 159-168	5	25
22	Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance. <i>Thoracic Cancer</i> , <b>2019</b> , 10, 1096-1102	3.2	1
21	Co-mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. <i>Journal of Cellular and Molecular Medicine</i> , <b>2019</b> , 23, 6812-6821	5.6	7
20	Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK-positive non-small cell lung cancer: A retrospective, real-world study. <i>Cancer Medicine</i> , <b>2019</b> , 8, 5823-5830	4.8	4
19	Sequential therapy according to distinct disease progression patterns in advanced -positive non-small-cell lung cancer after crizotinib treatment. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2019</b> , 31, 349-356	3.8	2
18	Impact of crizotinib on long-term survival of -positive advanced non-small-cell lung cancer: A Chinese multicenter cohort study. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , <b>2019</b> , 31, 481-488	3.8	2
17	Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis <b>2019</b> , 7, 341		74
16	Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 9243-9251	3.6	8
15	Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey. <i>Lung Cancer</i> , <b>2019</b> , 128, 91-100	5.9	38
14	Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. <i>Lung Cancer</i> , <b>2018</b> , 118, 128-133	5.9	33
13	Distinct MET Protein Localization Associated With MET Exon 14 Mutation Types in Patients With Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , <b>2018</b> , 19, e391-e398	4.9	8
12	Evaluation of calculating carboplatin dosage in carboplatin-pemetrexed therapy as the first-line therapy for Chinese patients with advanced lung adenocarcinoma. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 400-407	3.2	3

11	Betulinic acid exerts potent antitumor effects on paclitaxel-resistant human lung carcinoma cells (H460) via G2/M phase cell cycle arrest and induction of mitochondrial apoptosis. <i>Oncology Letters</i> , <b>2018</b> , 16, 3628-3634	2.6	19
10	Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas. <i>Lung Cancer</i> , <b>2018</b> , 122, 113-119	5.9	7
9	Survival of crizotinib continuation plus brain radiotherapy among ALK positive non-small cell lung cancer (NSCLC) patients with brain metastases during crizotinib treatment.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21142-e21142	2.2	
8	A real-world survival of subsequent therapy in ALK positive non-small cell lung cancer (NSCLC) patients with crizotinib resistance.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, e21093-e21093	2.2	0
7	Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 1716-1724	3.2	1
6	Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2018</b> , 9, 805-813	3.2	3
5	Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 3105-3112	2.2	99
4	Gemcitabine combined with cisplatin as adjuvant chemotherapy for non-small cell lung cancer: A retrospective analysis. <i>Thoracic Cancer</i> , <b>2017</b> , 8, 482-488	3.2	5
3	Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type. <i>Annals of Hematology</i> , <b>2017</b> , 96, 1477-1483	3	15
2	The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China. <i>Oncotarget</i> , <b>2017</b> , 8, 87442-87454	3.3	6
1	Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study. <i>Molecular and Clinical Oncology</i> , <b>2014</b> , 2, 87-92	1.6	7